A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Clinical trial NCT07225504 · RECRUITING

Trial details

NCT number: NCT07225504
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Secondary Progressive Multiple Sclerosis (SPMS)

Start date: 2025-11-11
Primary completion: 2030-12-03
Enrollment: 1275

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.